{"DataElement":{"publicId":"6161697","version":"1","preferredName":"Index Lesion Response irRC Measurable Category","preferredDefinition":"Text term to represent the overall disease response in the largest tumor lesion targeted by therapy using the  Immune-Related Response Criteria (irRC) criteria.","longName":"IDX-irRC-OVR-RESP-CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"6160008","version":"1","preferredName":"Index Lesion Response","preferredDefinition":"The largest tumor lesion targeted by therapy._Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","longName":"4472272v1.0:2193203v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"4472272","version":"1","preferredName":"Index Lesion","preferredDefinition":"The largest tumor lesion targeted by therapy.","longName":"C110961","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Index Lesion","conceptCode":"C110961","definition":"The most clinically significant tumor lesion targeted by therapy. The lesion is typically the largest or highest graded of the tumor foci detected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"01B516DB-2209-FA0F-E050-BB89AD4354CC","latestVersionIndicator":"Yes","beginDate":"2014-08-28","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-28","modifiedBy":"ONEDATA","dateModified":"2014-08-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2193203","version":"1","preferredName":"Response","preferredDefinition":"Response is any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","longName":"C25755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EACFDBFA-EFCE-25E6-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-12-09","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRC: Immune-Related Response Criteria-2009","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"68E1D2EB-E2A8-2125-E053-F662850A8485","latestVersionIndicator":"Yes","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-02","modifiedBy":"HARTLEYG","dateModified":"2018-04-05","changeDescription":"4/2/18 jk created for DCI study and iRECIST FG activity.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6161683","version":"1","preferredName":"irRC Measurable Overall Response Category","preferredDefinition":"A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria._Capable of being measured._An assessment of the overall response of the disease to the therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"6161683v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"4","maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"irCR","valueDescription":"irCR (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161693","version":"1","preferredName":"irCR (Immune-Related Response Criteria)","longName":"6161693","preferredDefinition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Complete Response","conceptCode":"C148193","definition":"Complete disappearance of all lesions (whether measurable or not, and no new lesions); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B50-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0B68-378D-E053-F662850AA125","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irPD","valueDescription":"irPD (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161694","version":"1","preferredName":"irPD (Immune-Related Response Criteria)","longName":"6161694","preferredDefinition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Progressive Disease","conceptCode":"C148196","definition":"Increase in tumor burden greater than or equal to 25 percent relative to nadir (minimum recorded tumor burden); confirmation by a repeat, consecutive assessment no less than 4 weeks from the date first documented.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B75-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0B8D-378D-E053-F662850AA125","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irPR","valueDescription":"irPR (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161695","version":"1","preferredName":"irPR (Immune-Related Response Criteria)","longName":"6161695","preferredDefinition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Partial Response","conceptCode":"C148194","definition":"Decrease in tumor burden greater than or equal to 50 percent relative to baseline confirmed by a consecutive assessment at least 4 weeks after first documentation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0B9A-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0BB2-378D-E053-F662850AA125","beginDate":"2018-04-02","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"},{"value":"irSD","valueDescription":"irSD (Immune-Related Response Criteria)","ValueMeaning":{"publicId":"6161696","version":"1","preferredName":"irSD (Immune-Related Response Criteria)","longName":"6161696","preferredDefinition":"Not meeting criteria for irCR or irPR, in absence of irPD.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria Stable Disease","conceptCode":"C148195","definition":"Not meeting criteria for irCR or irPR, in absence of irPD.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691F4496-0BBF-378D-E053-F662850AA125","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"691F4496-0BD8-378D-E053-F662850AA125","beginDate":"2017-10-12","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6161682","version":"1","preferredName":"Immune-Related Response Criteria Measurable Overall Response Category","preferredDefinition":"A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria.:Capable of being measured.:An assessment of the overall response of the disease to the therapy.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C148192:C37894:C96613:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immune-Related Response Criteria","conceptCode":"C148192","definition":"A set of response criteria designed to capture additional response patterns observed with immune therapy beyond those described by Response Evaluation Criteria in Solid Tumors (RECIST) or WHO criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Measurable","conceptCode":"C37894","definition":"Capable of being measured.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Overall Response","conceptCode":"C96613","definition":"An assessment of the overall response of the disease to the therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"691BD3EB-0213-3970-E053-F662850A163C","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"ONEDATA","dateModified":"2018-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"irRC: Immune-Related Response Criteria-2009","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"691BD3EB-0224-3970-E053-F662850A163C","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"KNABLEJ","dateModified":"2018-10-23","changeDescription":"10/23/18 jk chg reg status to Standard for RECIST defined PV list; do not add PVs without checking latest version of guideline.  4/5/18 jk created for DCI study and immune RECIST FG activities.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5635324","version":"1","longName":"RECIST","context":"NCI Standards"},{"publicId":"6160006","version":"1","longName":"irRC","context":"NCI Standards"}]}],"AlternateNames":[{"name":"NCI Standards","type":"USED_BY","context":"NCI Standards"}],"ReferenceDocuments":[{"name":"Index lesion irRC overall res","type":"Preferred Question Text","description":"Index lesion irRC overall response","url":null,"context":"NCI Standards"},{"name":"irRC instruction","type":"COMMENT","description":"CDE captures the overall response of all Index lesions response.  Use CDE 6160058 to collect  individual Index lesion responses (log line).","url":null,"context":"NCI Standards"},{"name":"irRC","type":"Alternate Question Text","description":"Index lesion overall response","url":null,"context":"NCI Standards"}],"origin":"irRC: Immune-Related Response Criteria-2009","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"691F3E01-A346-3F80-E053-F662850A8D36","latestVersionIndicator":"Yes","beginDate":"2018-04-05","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2018-04-05","modifiedBy":"KNABLEJ","dateModified":"2018-10-26","changeDescription":"10-22-18 Registration status changed to Standard/TMT. 10/19/18 jk removed dup terms in LN. 4/5/18 jk created for DCI study and immune RECIST FG activities.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}